drugset / Trial / NCT01810796

Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial

NCT01810796

Phase 3 Unknown 300 enrolled Hadassah Medical Organization
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Working hypothesis and aims: 1) To explore the pathophysiology of postoperative troponin elevations and 2) whether ranolazine, a new anti-ischemic drug that has no effect on blood pressure or heart rate, prevents postoperative myocardial injury.

Timeline

Start
2013-12
Primary completion
2016-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranolazine Small molecule 500 mg
Subject Ranolazine Small molecule 1000 mg